» Articles » PMID: 22942183

Adaptor Protein Lnk Binds to and Inhibits Normal and Leukemic FLT3

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2012 Sep 4
PMID 22942183
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase with important roles in hematopoietic progenitor cell survival and proliferation. It is mutated in approximately one-third of AML patients, mostly by internal tandem duplications (ITDs). Adaptor protein Lnk is a negative regulator of hematopoietic cytokine signaling. In the present study, we show that Lnk interacts physically with both wild-type FLT3 (FLT3-WT) and FLT3-ITD through the SH2 domains. We have identified the tyrosine residues 572, 591, and 919 of FLT3 as phosphorylation sites involved in direct binding to Lnk. Lnk itself was tyrosine phosphorylated by both FLT3 ligand (FL)-activated FLT3-WT and constitutively activated FLT3-ITD. Both shRNA-mediated depletion and forced overexpression of Lnk demonstrated that activation signals emanating from both forms of FLT3 are under negative regulation by Lnk. Moreover, Lnk inhibited 32D cell proliferation driven by different FLT3 variants. Analysis of primary BM cells from Lnk-knockout mice showed that Lnk suppresses the expansion of FL-stimulated hematopoietic progenitors, including lymphoid-primed multipotent progenitors. The results of the present study show that through direct binding to FLT3, Lnk suppresses FLT3-WT/ITD-dependent signaling pathways involved in the proliferation of hematopoietic cells. Therefore, modulation of Lnk expression levels may provide a unique therapeutic approach for FLT3-ITD-associated hematopoietic disease.

Citing Articles

Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia.

Hormann F, Ostergaard A, van den Broek S, Boeree A, van de Ven C, Escherich G Hemasphere. 2025; 9(1):e70069.

PMID: 39840380 PMC: 11746935. DOI: 10.1002/hem3.70069.


Rare SH2B3 coding variants in lupus patients impair B cell tolerance and predispose to autoimmunity.

Zhang Y, Morris R, Brown G, Lorenzo A, Meng X, Kershaw N J Exp Med. 2024; 221(4).

PMID: 38417019 PMC: 10901239. DOI: 10.1084/jem.20221080.


A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia.

Nasimian A, Al Ashiri L, Ahmed M, Duan H, Zhang X, Ronnstrand L Int J Mol Sci. 2023; 24(4).

PMID: 36835239 PMC: 9959897. DOI: 10.3390/ijms24043830.


The Role of LNK (SH2B3) in the Regulation of JAK-STAT Signalling in Haematopoiesis.

Morris R, Butler L, Perkins A, Kershaw N, Babon J Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056081 PMC: 8781068. DOI: 10.3390/ph15010024.


LNK (SH2B3) inhibition expands healthy and Fanconi anemia human hematopoietic stem and progenitor cells.

Holdreith N, Lee G, Chandra V, Salinas C, Nicholas P, Olson T Blood Adv. 2021; 6(3):731-745.

PMID: 34844262 PMC: 8945310. DOI: 10.1182/bloodadvances.2021004205.


References
1.
Stirewalt D, Radich J . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65. DOI: 10.1038/nrc1169. View

2.
Oh S, Simonds E, Jones C, Hale M, Goltsev Y, Gibbs Jr K . Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010; 116(6):988-92. PMC: 2924231. DOI: 10.1182/blood-2010-02-270108. View

3.
Lin P, Jones D, Medeiros L, Chen W, Vega-Vazquez F, Luthra R . Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006; 126(4):530-3. DOI: 10.1309/JT5BE2L1FGG8P8Y6. View

4.
Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler H . Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood. 2007; 110(9):3360-4. PMC: 2200920. DOI: 10.1182/blood-2007-05-089326. View

5.
Bersenev A, Wu C, Balcerek J, Tong W . Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest. 2008; 118(8):2832-44. PMC: 2447929. DOI: 10.1172/JCI35808. View